Will Axsome Therapeutics stock go up?

According to Danelfin AI, Axsome Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.49%) is +7.67% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Axsome Therapeutics stock?

The Axsome Therapeutics target price is $244.35 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Axsome Therapeutics stock right now?

Axsome Therapeutics has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (58.49%) is +7.67% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Axsome Therapeutics stock is a good buy .

Is Axsome Therapeutics undervalued right now?

Based on analysts, the average price target downside for Axsome Therapeutics is 0.00% (1Y). According to Danelfin AI, Axsome Therapeutics has today an AI Score of 7/10 (Buy Rating).

What was the price range of Axsome Therapeutics stock over the past 12 months?

The Axsome Therapeutics stock price range over the past 12 months has been $100.39 - $255.17.

What is going on with Axsome Therapeutics stock in the last 3 months?

The Axsome Therapeutics stock performance in the last quarter has been +42.24%.

Does Axsome Therapeutics offer dividend payments?

No, Axsome Therapeutics does not currently pay dividends.

What is the current market capitalization of Axsome Therapeutics?

Axsome Therapeutics's market cap is $12.57B, as of 2026-07-03 08:00.

Axsome Therapeutics Inc (AXSM) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

AXSM AI-Powered Stock Analysis

AI Score Explanation

AI Score

Buy

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Axsome Therapeutics Inc today receives an AI Score of 7/10, which translates to a Buy rating. The stock has a 58% probability of outperforming the market in the next 3 months, which is 8% higher than the average probability of any stock (50%). The top positive contributors include the Chart Pattern (504d) (impact +2.18%), the Pharmaceuticals industry (+1.90%), and the Fundamentals Impact (Long Tail) (+1.82%). On the detractor side, the Fear & Greed Index (currently at 31, indicating fear) reduces probability by -0.93%, while Net Property, Plant & Equipment (in the bottom 20%) detracts -0.54%. Notable data points include Operating Cash Flow (Qtr Discrete) in the bottom 20% (value -20.7), which surprisingly contributes positively (+1.25%), while Beginning Cash in the top 30% (value 322.9M) adds +0.42%. However, ATR (14d Volatility) in the top 10% (value 8.84) detracts -0.40%, indicating high volatility weighs on the probability. Overall, the stock benefits from strong technical patterns and industry tailwinds, but faces headwinds from sentiment and volatility, resulting in a Buy rating with a solid probability edge over the market.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+4.44%
Direction and strength of recent price movements
Sentiment+1.37%
How analysts and the market view the stock
Earnings Quality+0.94%
Stability and reliability of reported earnings
Valuation+0.86%
How the stock is priced relative to its fundamentals
Size & Liquidity+0.42%
Company size and trading liquidity
Growth+0.26%
Expected pace of revenue and earnings expansion

Volatility-0.40%
How much the stock price tends to fluctuate
Profitability-0.22%
Profitability and operating efficiency metrics

AXSM probability advantage of beating the market (3M):

+7.67%

AI Score

Buy

Axsome Therapeutics (AXSM) has an AI Score of 7/10 (Buy) because, according to an overall analysis, it has a probability advantage of +7.67% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of AXSM (58.49%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
AXSM probability advantage of beating the market (3M)+7.67%
AXSM probability of beating the market (3M)58.49%

AXSM probability advantage of beating the market (3M): +7.67%

The AI-powered overall analysis of Axsome Therapeutics (AXSM) is based on the 26 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of AXSM:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (504d)	figure_58	N/A	+2.18%
Sentiment	Industry (GICS)	Pharmaceuticals	N/A	+1.90%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.82%
Fundamental	Operating Cash Flow (Qtr Discrete)	-20.7		+1.25%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.93%
Technical	Chart Pattern (180d)	figure_78	N/A	+0.78%
Technical	Chart Pattern (120d)	figure_132	N/A	+0.62%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	0.57		-0.54%
Technical	Chart Pattern (90d)	figure_33	N/A	+0.47%
Technical	Chart Pattern (252d)	figure_3	N/A	+0.46%
Fundamental	Upgrade to unlock			+0.42%
Fundamental	Upgrade to unlock			-0.42%
Technical	Upgrade to unlock			-0.40%
Sentiment	Upgrade to unlock			+0.34%
Sentiment	Upgrade to unlock			+0.31%

Rest of Alpha Signals: -0.58%

AXSM probability advantage of beating the market (3M)Total:+7.67%
AXSM AI Score

Significant changes Vs previous day

AXSM Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$244.35
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

AXSM Proven Buy Signal & Price Forecast

This is the price chart for AXSM from January 2, 2026 until today. The chart indicates, in green, the 59 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

AXSM Average Past Performance & Win Rate

Three months after its 441 Buy signals since June 2026, AXSM had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

441 Past AXSM Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+253.47%
Average Alpha				+245.73%
Win Rate (% Positive Perf.)				73.68%
% Positive Alpha				72.37%

AXSM Past Buy Signals Performance

Performance and alpha after 1, 3, 6 months, and 1 year, for each of the 424 days that AXSM was rated a Strong Buy/Buy (AI Score 7 to 10) since June 2026.

Date	Perf. 1M	Perf. 3M	Perf. 6M	Perf. 1Y	Alpha. 1M	Alpha. 3M	Alpha. 6M	Alpha. 1Y
2017-01-05	-27.56%	-44.09%	-13.39%	-11.81%	-28.68%	-48.09%	-20.32%	-32.58%
2017-01-09				-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
Showing 1 to 10 of 424 days 1 2 3 4 5 ... 43
-	-	-	-	-	-	-	-	-

Date	AI Score	Perf. 1M	Perf. 3M	Perf. 6M	Perf. 1Y	Alpha. 1M	Alpha. 3M	Alpha. 6M	Alpha. 1Y

AXSM Frequently Asked Questions

Will Axsome Therapeutics stock go up?
According to Danelfin AI, Axsome Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.49%) is +7.67% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Axsome Therapeutics stock?
Is it a good time to buy, sell, or hold Axsome Therapeutics stock right now?
Is Axsome Therapeutics undervalued right now?
What was the price range of Axsome Therapeutics stock over the past 12 months?
What is going on with Axsome Therapeutics stock in the last 3 months?
Does Axsome Therapeutics offer dividend payments?
What is the current market capitalization of Axsome Therapeutics?

Axsome Therapeutics Inc Company Profile

Axsome Therapeutics, Inc. is a biopharmaceutical establishment engaged in the advancement of unique treatments for disorders of the central nervous system (CNS) throughout the United States. The notable assets within its product arsenal feature Auvelity (dextromethorphan-bupropion), a compound targeting N-methyl-D-aspartate receptors with versatile activity; this formulation indicated for alleviating major depressive disorder symptoms. Another product under their banner is Sunosi (solriamfetol), an innovative medication designed to counter excessive daytime sleepiness prevalent in narcolepsy or obstructive sleep apnea patients.

Moreover, several promising treatments are coursing through their developmental pipeline. Notably, AXS-05 has entered Phase III clinical trials as a potential therapeutic option for agitation associated with Alzheimer's disease and has already successfully navigated through Phase II trials for smoking cessation treatment.

And then we have AXS-07, an experimental medicine that recently concluded its Phase III trials and might soon become part of the armamentarium against acute migraines. Concurrently, AXS-12 is emerging from its Phase III trial trenches and may potentially revolutionize narcolepsy treatment protocols.

AXS-14 showcases itself as a potent and selective norepinephrine reuptake inhibitor that may hold promise against fibromyalgia and myriad other conditions after effectively concluding Phase III trials. Lastly, solriamfetol – a dual-action dopamine and norepinephrine reuptake inhibitor - has shown positive outcomes in Phase 2 studies targeting attention-deficit/hyperactivity disorder, progressing into phase 2 investigations focusing on major depression, binge eating, and shift work maladies.

The innovation-driven Axsome Therapeutics also engages in research collaborations; it collaborates with Duke University for studying AXS-05 regarding smoking cessation applications. With roots traced back to 2012, this New York-based company continues to excel in its field.

Sector:Health Care
Country:United States
Industry:Pharmaceuticals
Address:One World Trade Center, 29Th Floor, New York City
Employees:925
Website:axsome.com

Pros

Proprietary drug development platform for CNS

Diversified pipeline addressing multiple CNS indications

Intellectual property protection for approved therapies

High switching costs for chronic CNS medication

Addressing unmet medical needs in CNS disorders

Cons

High capital intensity of pharmaceutical R&D

Pros

Cons

Company

AI Score

Compare

AYTUAytu Biopharma Inc

SUPNSupernus Pharmaceuticals Inc

BTAIBioXcel Therapeutics Inc

AVXLAnavex Life Sciences Corp

AMLXAmylyx Pharmaceuticals Inc

Company

AI Score

Compare

AXSM Top 10 Industry Stocks

Pharmaceuticals

	Company	AI Score	Compare
1	PAHCPhibro Animal Health Corp
2	GSKGSK plc
3	EYPTEyePoint Inc
4	LBRXLB Pharmaceuticals Inc
5	RAPPRapport Therapeutics Inc
6	JAZZJazz Pharmaceuticals PLC
7	LENZLENZ Therapeutics Inc
8	SEPNSepterna Inc
9	AZNAstraZeneca PLC
10	PHVSPharvaris NV

	Company	AI Score	Compare

AXSM Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc
2	IMNMImmunome Inc
3	VRDNViridian Therapeutics Inc
4	PAHCPhibro Animal Health Corp
5	GSKGSK plc
6	ZYMEZymeworks Inc
7	RNAAvidity Biosciences Inc
8	EYPTEyePoint Inc
9	LBRXLB Pharmaceuticals Inc
10	EBSEmergent BioSolutions Inc

	Company	AI Score	Compare

AXSM Stock AI Analysis